Fintel reports that on August 21, 2025, JP Morgan downgraded their outlook for Alcon (NYSE:ALC) from Overweight to Neutral.

Alcon (NYSE:ALC) stock continues to decline as J.P. Morgan downgrades the company following mixed Q2 2025 results and lowered sales guidance. Read more here.

The analysts cut its rating on Alcon shares to “neutral” from “overweight” and lowered its price target to SFr 62.8 for June 2027, down from SFr 94.7 for June 2026. The reduced target reflects lower ...

JPMorgan analyst David Adlington downgraded Alcon (ALC) to Neutral from Overweight with a price target of $77.53, down from $105.88. The company ...

Walmart (NYSE: WMT) stock fell 2.7% after the retail giant reported mixed second-quarter results, with revenue exceeding expectations but earnings falling short of analyst estimates. The retail giant ...

Alcon affirmed fiscal year 2025 adjusted earnings of $3.05-$3.15 versus consensus of $3.12. The company lowered 2025 sales guidance from $10.4 billion-$10.5 billion to $10.3 billion-$10.4 billion, ...

 Alcon plans to acquire STAAR Surgical through a definitive merger agreement, according to a press release.

Alcon is building out its portfolio of lens implants, with a $1.5 billion deal to acquire the flagging Staar Surgical and its focus on correcting nearsightedness.

H.C. Wainwright upgraded CoreWeave (CRWV) to Buy from Neutral with an $180 price target. The stock's valuation "has sunk deep enough," the analyst tells investors in a research note. Arete also ...

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ: STAA), the manufacturer of the Implantable Collamer® Lens ...

Alcon Agrees to Acquire STAAR Surgical STAAR Surgical is a leader in refractive surgery using Implantable Collamer Lenses, offering solutions for moderate to high myopes Acquisition of STAAR is ...

Alcon launched Tryptyr, a treatment for the signs and symptoms of dry eye disease, in the U.S. Tryptyr (acoltremon ophthalmic solution 0.003%) is a TRPM8 receptor agonist that showed a &ldquo ...